Korea S.E.
06:00:00 2024-05-16 pm EDT
5-day change
1st Jan Change
4,300
KRW
+2.38%
+4.37%
+2.63%
Komipharm International Co., Ltd. announced that it has received KRW 15 billion in funding from a group of investors
On July 6, 2023, Komipharm International Co., Ltd. closed the transaction.
Komipharm International Co., Ltd. announces an Equity Buyback for 241,545 shares.
Mar. 20
CI
Komipharm International Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 20
CI
Komipharm International Co., Ltd. authorizes a Buyback Plan.
Mar. 19
CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 14
CI
Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
CI
Komipharm International Co., Ltd. announced that it has received KRW 15 billion in funding from a group of investors
23-07-05
CI
Komipharm International Co., Ltd. announced that it expects to receive KRW 15 billion in funding
23-07-03
CI
Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Komipharm International Co., Ltd.'s Equity Buyback announced on September 23, 2022, has expired.
22-12-22
CI
Tranche Update on Komipharm International Co., Ltd.'s Equity Buyback Plan announced on September 23, 2022.
22-12-16
CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
Komipharm International Co., Ltd. announces an Equity Buyback for 146,842 shares.
22-09-23
CI
Komipharm International Co., Ltd. authorizes a Buyback Plan.
22-09-22
CI
Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-12
CI
Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-13
CI
Komipharm International Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-16
CI
Komipharm International Australia Pty. Ltd. announced that it has received AUD 3.58605 million in funding from Komipharm International Co., Ltd.
21-12-22
CI
Komipharm International Australia Pty. Ltd. announced that it expects to receive AUD 3.58605 million in funding from Komipharm International Co., Ltd.
21-12-16
CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-12
CI
Komipharm International Co., Ltd. announced that it has received KRW 10 billion in funding
21-04-01
CI
Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding
21-03-30
CI
Komipharm International Co., Ltd. announced that it has received KRW 10 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd. and other investors
19-06-09
CI
Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd. and other investors
19-06-04
CI
Komipharm International Co., Ltd. announced that it has received KRW 10 billion in funding from W Asset Management Co., Ltd., Susung Asset Management Co., Ltd., Focus Asset Management Co., Ltd., DB Financial Investment Co.,Ltd., Investment Arm
18-06-03
CI
Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding from W Asset Management Co., Ltd., Susung Asset Management Co., Ltd., Focus Asset Management Co., Ltd., DB Financial Investment Co.,Ltd., Investment Arm
18-05-30
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
More about the company
1st Jan change
Capi.
+2.63% 223M -11.83% 79.42B +28.00% 3.8B -1.39% 3.23B +21.28% 1.75B -3.25% 1.61B -18.63% 1.36B -1.17% 1.3B -6.77% 1.22B +2.34% 1.11B
Veterinary Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
KOMIPHARM INTERNATIONAL CO., LTD. 